Top GSK/ViiV scientist who co-invented an HIV blockbuster books a trip to biotech
Brian A. Johns, a top HIV scientist at GSK’s ViiV, is following the well-traveled road into biotech.
Noted as a co-inventor of dolutegravir — a bestselling HIV drug marketed alone as Tivicay — as well as the long-acting cabotegravir, Johns was featured in PhRMA’s Go Boldly campaign celebrating the industry’s breakthrough successes and the people who made them happen. And now he’s joining HemoShear in Charlottesville, VA as their new CSO.
John’s last position at GSK, after a 20-year stint, was VP in charge of external discovery sciences, where he worked with collaborators like UNC and Qura on a cure for HIV/AIDS. But he’s headed into new R&D arenas now.
In a statement, Johns said he was particularly excited to be focusing on rare pediatric metabolic diseases. A couple of years ago HemoShear also lined up a $470 million collaboration with Takeda on NASH, another big indication that has attracted a slew of competitors looking to make their mark.